Lakshmi Nayak, MD

Dr. Chieh-Lung Cheng reports a gastrointestinal bleeding event in one patient that resolved with dose reduction, allowing continued therapy.

Dr. Lakshmi Nayak turns to the future role of BTK inhibitors in frontline and maintenance therapy.

Dr. Chieh-Lung Cheng describes his practical monitoring approach in Taiwan, where tirabrutinib is the only BTK inhibitor approved for relapsed/refractory PCNSL.

Dr. Lakshmi Nayak asks Dr. Motoo Nagane about real-world patient selection and dose maintenance in Japan, drawing on several years of post-approval experience.

Dr. Chieh-Lung Cheng addresses where BTK inhibitors fit in relapsed/refractory PCNSL and how he selects patients, noting that in Taiwan tirabrutinib is used as monotherapy rather than in combination.

Dr. Lakshmi Nayak asks Dr. Motoo Nagane, as a neurosurgeon and neuro-oncologist, about the pharmacologic importance of CNS penetration.

Dr. Christian Grommes revisits the early ibrutinib experience, when nearly every B-cell malignancy appeared responsive to BTK inhibition, and recalls the setback in non-CNS diffuse large B-cell lymphoma, where responses and progression-free survival were disappointing.

Dr. Lakshmi Nayak transitions the discussion to the evolution of the BTK inhibitor class, the program's second module.

Dr. Motoo Nagane discusses the evolving treatment pathway for primary CNS lymphoma (PCNSL) in Japan following the approval of tirabrutinib for relapsed or refractory disease.

Dr. Chieh-Lung Cheng describes the impact of tirabrutinib availability on the management of relapsed/refractory primary CNS lymphoma (PCNSL) in Taiwan.

Dr. Christian Grommes discusses the emerging role of BTK inhibitors in relapsed/refractory primary CNS lymphoma (PCNSL), focusing on U.S. off-label use and ongoing clinical investigation.

Experts unpack BTK inhibitor use for relapsed primary CNS lymphoma, sharing Japan and Taiwan real‑world data, trials, and tirabrutinib insights.

Experts debate BTK inhibitors for primary CNS lymphoma, sharing trial and real-world insights on tirabrutinib and options for relapsed disease.

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Dr. Lakshmi Nayak presents results from the Phase II PROSPECT study, demonstrating that tirabrutinib monotherapy yields a 66.7% overall response rate and a manageable safety profile in patients with relapsed or refractory primary central nervous system lymphoma, supporting its potential as an effective treatment option in this challenging population.

Lakshmi Nayak, MD, discusses the mechanism of action of emavusertib and the study of this drug relapsed/refractory primary and secondary CNS lymphoma.

Lakshmi Nayak, MD, discusses the investigation of axi-cel in patients with relapsed/refractory primary and secondary CNS lymphoma.

Lakshimi Nayak, MD, discusses the diagnosis of patients with primary CNS lymphoma.

Primary central nervous system lymphoma is a rare and aggressive variant of extranodal non-Hodgkin lymphoma that occurs in the brain, spinal cord, cerebrospinal fluid, or eyes in the absence of systemic disease.